Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trametinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 17/20 | 0.98 |
| ▸ | MAP2K2 known ✓ | P36507 | 2/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.37 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trametinib SCHEMBL30301264 | 1.00 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL29355100 | 0.99 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL170938 | 0.99 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL29363416 | 0.99 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419395 | 0.98 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419085 | 0.98 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419392 | 0.98 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL30035834 | 0.98 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419017 | 0.98 | MAP2K1 (0.97) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| SCHEMBL26815709 | 0.97 | MAP2K1 (0.96) | MAP2K1MAP2K2ABCB1NOX4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706770-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| EP-4397376-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-4159217-B1 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | NOVARTIS AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| EP-4159217-A1 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2023-04-05 | — | — | EP | disclosed |
| EP-3560498-A1 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-2488033-B1 | Combination comprising an MEK inhibitor and a B-raf inhibitor | NOVARTIS AG (CH) | 2019-06-12 | — | — | EP | disclosed |